[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neonatal-hyperbilirubinemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neonatal-hyperbilirubinemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,77,108,138,167,191,221,240,268],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054192","predictors-of-rebound-hyperbilirubinemia-study-100054192",false,"NCT07694635","Predictors of Rebound Hyperbilirubinemia Study","Predictors of Rebound Hyperbilirubinemia After Phototherapy in Neonates","Inclusion Criteria:\n\n* Neonates admitted to the NICU with neonatal hyperbilirubinemia\n* Gestational age ≥35 weeks\n* Requirement for phototherapy according to institutional protocol and current guideline-based phototherapy thresholds\n* Receipt of standard and\u002For intensive phototherapy\n* Availability of bilirubin measurements before, during, and after phototherapy\n* Availability of rebound bilirubin measurement within 48 hours after phototherapy discontinuation\n* Written informed consent obtained from parents or legal guardians, if required by the ethics committee\n\nExclusion Criteria:\n\n* Major congenital anomalies\n* Conjugated hyperbilirubinemia\n* Neonates requiring exchange transfusion before completion of initial phototherapy\n* Severe perinatal asphyxia\n* Proven or suspected inborn errors of metabolism affecting bilirubin metabolism\n* Significant congenital liver disease\n* Neonates transferred to another center before completion of rebound bilirubin follow-up\n* Missing or incomplete clinical or laboratory data\n* Absence of rebound bilirubin measurement within 48 hours after phototherapy discontinuation\n* Parents or legal guardians declining participation, if consent is required","ALL","2 Hours","28 Days",{"count":20,"type":21},300,"ESTIMATED","2 Days","OBSERVATIONAL","\\## Brief Summary\n\nNeonatal hyperbilirubinemia is one of the most common causes of neonatal hospitalization and phototherapy treatment. Although phototherapy is highly effective, rebound hyperbilirubinemia following discontinuation of phototherapy may occur in some infants and may require repeat treatment. Early identification of neonates at risk for clinically significant rebound hyperbilirubinemia could help optimize discharge timing and reduce unnecessary hospital stay and repeat bilirubin testing.\n\nThis prospective observational study aims to evaluate the predictors of rebound hyperbilirubinemia after phototherapy discontinuation in neonates admitted to the NICU. Particular focus will be placed on the role of delta total serum bilirubin (ΔTSB), defined as the difference between the phototherapy threshold and the measured bilirubin level at the time of phototherapy discontinuation. Clinical, demographic, laboratory, hemolytic, feeding-related, and phototherapy-related variables will also be analyzed.\n\nThe primary outcome will be clinically significant rebound hyperbilirubinemia requiring repeat phototherapy within 24-48 hours after discontinuation of the initial phototherapy treatment. Secondary outcomes include rebound bilirubin levels, duration of hospitalization, and factors associated with repeat phototherapy.",[26,27],"Neonatal Hyperbilirubinemia","Rebound Hyperbilirubinemia",[27,29,30,31,32],"Neonatal Jaundice","Phototherapy","Neonate","Repeat Phototherapy","NOT_YET_RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":21},"2026-06-15",{"date":41,"type":21},"2026-11",{"name":43,"class":44},"Haseki Training and Research Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100644802","bilirubin-thresholds-in-preterm-infants-on-neonatal-intensive-care-units-the-b-nice-trial-100644802","NCT07674537","Bilirubin Thresholds in Preterm Infants on Neonatal Intensive CarE Units: The B-NICE Trial","B-NICE","Inclusion Criteria:\n\n* Gestational age at birth \\\u003C30+0 weeks.\n* Admission to a participating NICU within 24 hours after birth.\n* Parental consent according to the approved consent procedure\n\nExclusion Criteria:\n\n* Major congenital anomalies, excluding intraventricular hemorrhage, expected to affect survival or neurodevelopmental outcome.\n* Antenatal diagnosis of immune hemolytic disease of the fetus or newborn (such as RhD antagonism) requiring protocolized alternative management.","24 Weeks","29 Weeks",{"count":56,"type":21},680,"INTERVENTIONAL",[59],"NA","Rationale: Neonatal hyperbilirubinemia is highly prevalent in very preterm infants born \\\u003C30 weeks. Since 2008, uniform Dutch phototherapy thresholds for preterm infants have been used nationwide, largely based on consensus. Consequently, \\>80% of very preterm infants receive phototherapy for several days, accompanied by repeated blood sampling and reduced opportunities for skin-to-skin care. The corresponding UK National Institute for Health and Care Excellence (NICE) guideline applies higher (less strict) thresholds, which may reduce overtreatment, but comparative safety for very preterm infants has not been established in a randomized trial. The investigators hypothesize that using NICE thresholds is non-inferior to Dutch thresholds for survival without neurodevelopmental impairment (NDI) at two years' corrected age, while reducing treatment burden.\n\nObjective: Primary: To determine whether initiating phototherapy according to NICE thresholds is non-inferior to Dutch thresholds with regard to survival without NDI at two years' corrected age in infants born \\\u003C30 weeks of gestation. Secondary: To compare phototherapy exposure (incidence, duration and cumulative exposure) and monitoring burden (e.g., number of bilirubin blood samples, temperature instability, biomarkers of oxidative stress (subpopulation)), and to evaluate parent-infant outcomes (skin-to-skin contact time, parental stress\u002Fsatisfaction), and nursing workload (time dedicated to bilirubin-related care).\n\nStudy design: Nationwide multicenter, parallel-group, open-label randomized non-inferiority trial with 1:1 allocation, stratified by center and gestational age category (\\\u003C28 weeks and ≥28 weeks). Follow-up continues to the routine neurodevelopmental assessment at two years' corrected age. Planned project duration: 36 months.\n\nStudy population: Very preterm infants born \\\u003C30+0 weeks of gestation, admitted to a participating Dutch NICU within 24 hours after birth.\n\nIntervention: Bilirubin monitoring and phototherapy according to one of two threshold strategies: (1) current Dutch phototherapy thresholds (control) or (2) thresholds from the UK NICE guideline (intervention). Phototherapy is delivered using standard NICU devices.\n\nMain study parameters\u002Fendpoints: Primary endpoint: survival without NDI at two years' corrected age. NDI is defined as Bayley Scales of Infant and Toddler Development, fourth Edition, Dutch Version (BSID-IV-NL) cognitive and\u002For motor composite score \\\u003C85 and\u002For hearing impairment and\u002For visual impairment.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: Both strategies reflect accepted standards of care with routine bilirubin monitoring. Incremental burden consists mainly of additional registration (phototherapy use, bilirubin sampling, skin-to-skin contact, temperature instability), parental questionnaires and, in selected centers, collection of stress-related biomarkers from urine, feces, or waste material from routine blood samples to explore the physiological impact of phototherapy. No biobanking for future unspecified research is planned. The investigators will also use routinely collected and stored monitor data to assess sleep (sleep-wake states and sleep fragmentation) in a subset of infants. Neurodevelopmental follow-up at two years corrected age is routine care in Dutch NICUs. Bilirubin levels above thresholds in both groups will be mitigated by routine monitoring and management according to this study protocol. The study is group-related because bilirubin management and potential neurotoxicity thresholds are specific to very preterm infants.",[26,62,63,30,64],"Treatment Decisions","Neurodevelopmental Outcome","Exchange Transfusion",[66,67],"neonatal jaundice","preterm infants \u003C 30 weeks GA","2026-06-24",{"date":70,"type":37},"2026-06-29",{"date":72,"type":21},"2026-08-01",{"date":74,"type":21},"2029-11-01",{"name":76,"class":44},"University Medical Center Groningen",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":22,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":57,"phases":87,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":45},"100637507","foot-reflexology-and-massage-in-neonates-receiving-phototherapy-100637507","NCT07610811","Foot Reflexology and Massage in Neonates Receiving Phototherapy","Effects of Foot Reflexology and Massage on Total Serum Bilirubin, Physiological Parameters, and Stress in Neonates Receiving Phototherapy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Neonates whose parents\u002Flegal guardians have signed the informed consent form and agreed to participate in the study\n* Neonates born between 34 and 41 weeks of gestation\n* Birth weight of 2500 g or above\n* Not mechanically ventilated\n* No nasogastric tube\n* Stable vital signs\n* No elevated acute phase reactants during phototherapy treatment\n* Indirect bilirubin level between 12 and 28 mg\u002FdL at admission to the neonatal intensive care unit\n* Not receiving antibiotic treatment during the study\n* Aged between 2 and 10 days\n* No health problems other than indirect hyperbilirubinemia.\n\nExclusion Criteria:\n\n* Presence of any neurological anomaly\n* Presence of any congenital anomaly\n* Jaundice due to ABO incompatibility\n* Jaundice due to Rh incompatibility\n* Presence of dermal anomalies\n* Diagnosis of hyperbilirubinemia within the first 24 hours after birth\n* Diagnosis of direct hyperbilirubinemia","10 Days",{"count":86,"type":21},105,[59],"Neonatal hyperbilirubinemia is a common condition in newborns and is frequently treated with phototherapy. In addition to standard treatment, non-pharmacological interventions such as massage and foot reflexology may help reduce bilirubin levels and improve physiological stability and stress in newborns.\n\nThis randomized controlled trial aims to evaluate the effects of foot reflexology and body massage on total serum bilirubin levels, physiological parameters (heart rate, respiratory rate, oxygen saturation, and body temperature), and stress levels in neonates receiving phototherapy.\n\nA total of 105 newborns will be randomly assigned to three groups: foot reflexology, body massage, and control group. Interventions will be applied before phototherapy sessions, and outcomes will be measured before and after the intervention.\n\nThe findings of this study are expected to provide evidence for the use of non-invasive complementary methods in reducing bilirubin levels and improving clinical outcomes in newborns.",[26],[91,92,30,31,93,94,95,96,97,98],"Foot Reflexology","Neonatal Massage","Hyperbilirubinemia","Bilirubin","Non-pharmacological Intervention","Complementary Therapy","Neonatal Stress","Physiological Parameters","2026-05-20",{"date":101,"type":37},"2026-05-28",{"date":103,"type":21},"2026-05-09",{"date":105,"type":21},"2027-05-08",{"name":107,"class":44},"Aydin Adnan Menderes University",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":57,"phases":119,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":45},"100555882","phase-4-efficacy--safety-of-oral-adjuvants-to-phototherapy-in-neonatal-hyperbilirubinemia-100555882","NCT06517862","Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia","Efficacy and Safety of Oral Zinc Sulphate and Ursodeoxycholic Acid as Adjuvants to Phototherapy in Management of Neonatal Non-Hemolytic Unconjugated Hyperbilirubinemia","Inclusion Criteria:\n\n* neonates with both genders\n* neonates with gestational age ≥ 32 weeks\n* neonates who can tolerate enteral feeding\n* diagnosed with unconjugated non-hemolytic hyperbilirubinemia\n* Phototherapy is required within the first week of life.\n\nExclusion Criteria:\n\n* Neonates with seizures, hydrops fetalis, hypoxic-ischemic encephalopathy, or major congenital anomalies\n* Neonates who have had an exchange transfusion within 24 hours\n* neonates have evidence of hemolytic causes of jaundice (e.g., ABO and RH\n* incompatibility, glucose 6-phosphate dehydrogenase deficiency)\n* neonates who have reported hypersensitivity to zinc sulfate or ursodeoxycholic acid.","1 Day","1 Month",{"count":118,"type":21},80,[120],"PHASE4","Neonatal jaundice, or neonatal hyperbilirubinemia, is a common medical issue in the first two weeks of life, causing prolonged hospitalization and readmissions. It results from elevated total serum bilirubin (TSB) and is manifested as yellowish discoloration of the skin, sclera, and mucous membrane. Clinical jaundice appears in about 60% of term neonates and 80% of preterm infants within the first week of life. Pathologic hyperbilirubinemia occurs when bilirubin levels increase by more than 5 mg\u002FdL\u002Fday or 0.2 mg\u002FdL\u002Fhour, or when jaundice lasts longer than two to three weeks in full-term infants. In preterm infants, unconjugated hyperbilirubinemia is of particular concern due to their permeable blood-brain barrier and underdeveloped brain. Phototherapy is widely used to reduce or prevent the rise of serum unconjugated bilirubin levels and reduce the need for exchange transfusions. However, phototherapy has both immediate and long-term side effects, and it can only decrease accumulated UCB but does not prevent its accumulation. There is a growing potential to explore novel adjuvant treatments to increase bilirubin clearance, decrease phototherapy duration, and decrease exchange transfusion rate.",[26],[124,30,125,126,127],"Neonatal hyperbilirubinemia","exchange transfusion","Zinc sulfate","Ursodeoxycholic acid","RECRUITING","2026-03-16",{"date":131,"type":37},"2026-03-18",{"date":133,"type":37},"2024-09-01",{"date":135,"type":21},"2026-06-30",{"name":137,"class":44},"Amira Adel Fouly",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":18,"enrollmentInfo":147,"targetDuration":4,"studyType":57,"phases":149,"briefSummary":151,"conditions":152,"keywords":153,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":45},"100580092","early-phase-1-modified-diagnosis-and-treatment-of-neonatal-hemolysis-with-etcoc-in-snh-100580092","NCT06832800","Modified Diagnosis and Treatment of Neonatal Hemolysis With ETCOc in sNH","Modified Diagnosis and Treatment of Neonatal Hemolysis Incorporated With ETCOc Measurement in Severe Neonatal Hyperbilirubinemia Management","MDTinsNH","Inclusion Criteria: Inclusion Criteria:\n\nInfants with gestational age of 35(+0) to 41(+6) weeks and birth weight ≥ 2500 grams\n\n* Infants with severe neonatal hyperbilirubinemia, including those whose serum total\n* bilirubin (TSB) levels reach above 20 mg\u002FdL or whose TSB levels at any time reach within 2 mg\u002FdL of the exchange transfusion threshold (i.e., TSB \\> (threshold - 2) mg\u002FdL).\n\nExclusion Criteria:\n\n* Infants with definite congenital genetic metabolic diseases, chromosomal or genetic disorders, or severe malformations.","4 Hours",{"count":148,"type":21},250,[150],"EARLY_PHASE1","The goal of this clinical trial is to learn if modified diagnosis and treatment (MDT) of neonatal hemolysis (a common cause to newborn jaundice) incorporated with ETCOc measurement (a non-invasive measurement of exhaled gas) works to prevent brain damage in newborns with severe hyperbilirubinemia (sNH). It will also learn about the. occurrence of cranial MRI in the study participants. The main questions it aims to answer are:\n\n* Does MDT lower the possibilities participants have brain damage before the age of one?\n* How many times of abnormalities in cranial MRI is detected before the age of one? Researchers will compare MDT to a control (a current management) to see if MDT works to prevent brain damage in newborns with sHN.\n\nParticipants will:\n\n* Take MDT or a control method in the management of sNH\n* Assess if there's brain damage before discharge and at the year of one\n* Record how many times of abnormalities in cranial MRI is detected before the age of one",[26],[154,155,156,157],"ETCOc","neonatal hemolysis","neonatal hyperbilirubinemia","modified","2026-01-15",{"date":160,"type":37},"2026-01-20",{"date":162,"type":37},"2025-07-21",{"date":164,"type":21},"2027-12-31",{"name":166,"class":44},"Women's Hospital School Of Medicine Zhejiang University",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":175,"sex":16,"minAge":176,"maxAge":18,"enrollmentInfo":177,"targetDuration":4,"studyType":57,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":45},"100619619","investigation-into-the-dynamic-variations-of-end-tidal-carbon-monoxide-concentration-etcoc-in-neonates-utilizing-non-dispersive-infrared-spectroscopy-and-its-implications-for-jaundice-management-100619619","NCT07346976","Investigation Into the Dynamic Variations of End-Tidal Carbon Monoxide Concentration (ETCOc) in Neonates Utilizing Non-Dispersive Infrared Spectroscopy and Its Implications for Jaundice Management","Investigation Into the Dynamic Variations of End-Tidal Carbon Monoxide Concentration (ETCOc) in Neonates Utilizing Non-Dispersive Infrared Spectroscopy and Its Implications for Jaundice Management.","ETCO","Inclusion Criteria:\n\n1. Newborns with gestational age of ≥ 37 weeks and birth weight of ≥ 2.5 kg;\n2. Newborns delivered by either vaginal delivery or cesarean section and with hospital stay of ≥ 3 days.\n\nExclusion Criteria:\n\n1. History of second-hand smoke exposure within 24 hours\n2. Parents smoke or are exposed to second-hand smoke.",true,"0 Days",{"count":178,"type":21},100,[59],"The objective of this study is to ascertain the diagnostic threshold of end-tidal carbon monoxide (ETCOc, adjusted for ambient CO levels) within the first three days postpartum, stratified by neonatal age at birth. Additionally, the study aims to evaluate the concordance of the risk range of ETCOc, as measured by non-dispersive infrared spectroscopy, with existing literature, and to assess the reliability of this technology in the management of neonatal hyperbilirubinemia.",[26],"2026-01-08",{"date":184,"type":37},"2026-01-16",{"date":186,"type":37},"2025-12-05",{"date":188,"type":21},"2027-07-01",{"name":190,"class":44},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":115,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":57,"phases":201,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":217,"locationsCount":220},"100570053","phase-2-newborn-jaundice---an-investigation-of-different-approaches-to-light-therapy-100570053","NCT06702241","Newborn Jaundice - An Investigation of Different Approaches to Light Therapy","Neonatal Hyperbilirubinemia - Phototherapeutic Treatment Strategies","Inclusion Criteria:\n\n* Hyperbilirubinemia with a total serum bilirubin level above the limit of necessary treatment according to the Danish Pediatric Society's guidelines\n* Birth weight \\>1800g\n* Gestational age \\>33+0\n\nExclusion Criteria:\n\n* Hyperbilirubinemia within the first 24 hours of life\n* Rapidly increasing serum levels of bilirubnemia indicating pathology or hemolysis","14 Days",{"count":200,"type":21},116,[202,203],"PHASE2","PHASE3","Background Neonatal jaundice affects about 60% of full-term newborns in their first week. If untreated, it can lead to permanent brain damage. In Denmark, 2-5% of newborns require phototherapy, the standard treatment. The maximum beneficial irradiance limit for phototherapy remains unclear. Furthermore, studies suggest that cycled phototherapy is as effective as continuous treatment.\n\nThis study aims to investigate the efficacy of elevating the irradiance of intensive phototherapy treatment regimens. This is to evaluate the dose-response relationship. Furthermore, the study aims to compare intermittent phototherapy to continuous phototherapy.\n\nMethods:\n\nIn a clinical randomized multicenter trial 116 newborns with non-hemolytic hyperbilirubinemia, gestational age \\>33+0, weight \\>1800g and no other significant neonatal diagnose will be randomized. All infants will receive 12 hours double therapy with a biliblanket and overhead light providing an intensity of either 40-, 55- or 70 µW\u002Fcm2\u002Fnm. Three groups will be treated with continuous phototherapy while a fourth group will receive intermittent phototherapy of 1,5 hours cycled intervals with an intensity of 70 µW\u002Fcm2\u002Fnm.\n\nParental experiences during treatment will be examined through a survey post treatment.\n\nThe study has been approved by the Regional Research Ethics Committee.\n\nPerspectives:\n\nUnderstanding the dose-response relationship of phototherapy will give an insight in the most effective way of treating neonatal jaundice. Intermittent therapy, if proven non-inferior, could facilitate more intimacy in the parent-infant relationship as well as benefits in initiating breastfeeding",[26],[207,208,209,210,156],"Cycled phototherapy","high irradiance phototherapy","Neonatal jaundice","Newborn jaundice","2025-11-17",{"date":213,"type":37},"2025-11-20",{"date":215,"type":37},"2025-01-14",{"date":74,"type":21},{"name":218,"class":219},"Regionshospital Nordjylland","OTHER_GOV",2,{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":115,"maxAge":18,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":4},"100604513","predictive-and-diagnostic-value-of-bind-score-in-assessment-of-severe-neonatal-jaundice-cases-in-neonatal-intensive-care-unit-100604513","NCT07150494","Predictive and Diagnostic Value of BIND Score in Assessment of Severe Neonatal Jaundice Cases in Neonatal Intensive Care Unit","Predictive and Diagnostic Value of BIND Score in Assessment of Severe Neonatal Jaundice Cases in NICU","Inclusion criteria:\n\nNewborn \\\u003C 28 days old Neonates with severe hyperbilirubinemia need extensive phototherapy impending exchange transfusion\n\nExclusion criteria:\n\nAge \\> 28 days old Neonates with any abnormal neurological signs suggesting neurological disease (hypoxic ischemic encephalopathy, muscle disease, …etc.).",{"count":118,"type":21},"Early detection and prevention of neonatal encephalopathy using BIND score.",[26],"2025-09-29",{"date":233,"type":37},"2025-09-30",{"date":235,"type":21},"2025-10-01",{"date":237,"type":21},"2026-10-01",{"name":239,"class":44},"Assiut University",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":175,"sex":16,"minAge":247,"maxAge":198,"enrollmentInfo":248,"targetDuration":4,"studyType":57,"phases":250,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":45},"100379264","safe-threshold-to-discontinue-phototherapy-in-hemolytic-disease-of-newborn-100379264","NCT04218318","Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn","Safe Threshold to Discontinue Phototherapy in Term and Late Preterm Infant With Hemolytic Disease of Newborn: A Randomized Controlled Trial","Inclusion Criteria:\n\nHealthy term and late-preterm neonates more than or equal 35 weeks gestation with hemolytic disease of newborn will be included. Enrolled infants should have evidence of hemolysis as defined by any of the following criteria:\n\n1. positive DAT and blood group iso-immunization (ABO \u002F RH incompatibility);and \u002For\n2. HGB decline by 2g\u002Fdl within 24hour.\n\nExclusion Criteria:\n\n* Major congenital abnormalities,\n* Surgical problems,\n* Direct hyperbilirubinemia\n* Sepsis","1 Hour",{"count":249,"type":21},84,[59],"We hypothesized that adopting a lower rather than a higher threshold for phototherapy discontinuation will be associated with reduced rates of rebound hyperbilirubinemia in term and late preterm neonates with hemolytic disease of newborn.\n\nObjectives: The investigators aimed to compare the safety of implementing low-threshold, compared to high- threshold, of TSB for phototherapy interruption in term and late preterm neonates with hemolytic disease of newborn.",[253,26],"Hemolytic Disease of Newborn",[255,256,93,257,30,258],"Jaundice","Newborn","Rebound hyperbilirubinemia","Hemolysis","2025-01-01",{"date":261,"type":37},"2025-01-03",{"date":263,"type":37},"2019-10-01",{"date":265,"type":21},"2027-01-01",{"name":267,"class":219},"Ministry of Health, Saudi Arabia",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":16,"minAge":176,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":57,"phases":279,"briefSummary":280,"conditions":281,"keywords":282,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":45},"100381410","transcutaneous-bilirubinometry-and-phototherapy-100381410","NCT04246229","Transcutaneous Bilirubinometry and Phototherapy","Transcutaneous Bilirubinometry in Neonatal Hyperbilirubinemia During and After Phototherapy: a Randomized Controlled Trial","TRABIN","Inclusion Criteria:\n\n* Neonates with indication for phototherapy for treatment of hyperbilirubinemia\n\nExclusion Criteria:\n\n* skinlesions located on the sternum interfering with transcutaneous measurement\n* exchange transfusion","2 Weeks",{"count":278,"type":21},130,[59],"A randomized Controlled trial comparing the use of transcutaneous bilirubinometry to serum bilirubin measurements (via blooddraws = standard care) in neonates born after a gestational age \\> 32 weeks and \\\u003C 15 days of age treated with Phototherapy for neonatal hyperbilrubinemia.",[26],[283,284,285,66,286],"transcutaneous bilirubinometry","phototherapy","neonatal icterus","newborn","2024-07-31",{"date":289,"type":37},"2024-08-02",{"date":291,"type":21},"2026-01-01",{"date":293,"type":21},"2027-05-01",{"name":295,"class":44},"Princess Amalia Children's Clinic"]